Company intelligence / Profile preview

CenterVue

Ownership: Private
Employees: ~51
Development stage: Commercial

Overview

CenterVue develops and commercializes highly automated diagnostic devices for early detection and management of sight-threatening ocular diseases. Its products are widely used in clinical practice for screening and monitoring progression of retinal pathologies such as diabetic retinopathy and macular degeneration. The company’s MAIA microperimeter received FDA clearance and has been adopted globally; its DRS fundus camera supports large-scale screening programs. Nearly 3,000 installations worldwide have contributed to global efforts in preventable blindness reduction.

Therapeutic areas: Ophthalmology
Modalities: Device (diagnostic systems)
Industry: Medical Imaging

Partnerships

Not specified; integrates with telemedicine platforms including proprietary Eye Knowledge Network

Beyond the preview

Go deeper on CenterVue.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CenterVue.

Explore the full profile